Amicus Therapeutics Inc. Stock
Price
Target price
€7.90
€7.90
1.940%
0.15
1.940%
€16.27
06.11.25 / Frankfurt
WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. gained 1.940% today.
Amicus Therapeutics Inc. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 16 € there is potential for a 102.53% increase which would mean more than doubling the current price of 7.9 € for Amicus Therapeutics Inc..
So far the community has only identified positive things for Amicus Therapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | 1.940% | 0.000% | 14.493% | -23.301% | -13.661% | -21.205% | -55.367% |
| Repligen Corp. | -2.110% | -4.521% | -1.357% | -7.280% | -11.718% | -30.512% | -27.452% |
| Opko Health Inc. | -4.410% | 1.428% | -10.643% | -12.108% | -18.157% | -35.868% | -64.380% |
| Hutchison China Meditech Ltd | 0.000% | 5.000% | -0.787% | -21.739% | -2.326% | 30.570% | -52.091% |
Comments
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
News
Amicus (FOLD) Q2 Revenue Jumps 22%
Amicus Therapeutics (NASDAQ:FOLD), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP
